SVRA

Savara Inc. [SVRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SVRA Stock Summary

Top 10 Correlated Stocks

SVRA

In the News

SVRA Financial details

Company Rating
-
Market Cap
700.41M
Income
-52.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-14.85
Forward P/E
-
PEG
-5.44
P/S
-
P/B
4.8
P/C
-
P/FCF
-13.05
Quick Ratio
18.88
Current Ratio
18.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-26%
ROE
-43%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.69-5.7
52W High
-38.5%
52W Low
+207.5%
RSI
60
Rel Volume
0.37
Avg Volume
791.03K
Volume
290.16K
Perf Week
16.48%
Perf Month
15.6%
Perf Quarter
-11.64%
Perf Half Y
-18.22%
-
-
-
-
Beta
0.697
-
-
Volatility
0.06%, 0.13%
Prev Close
2.16%
Price
3.075
Change
16.48%

Something similar

Top by Market Cap
VFINX
JPM
TSLA
FXAIX
VTI
Same Sector
CSU
OGEN
BTAI
603538.SS
ABTI
Top Correlated Stocks
SBS
0003.HK
SMSAAM.SN
Similar Market Cap
FJAN
1468.HK
BSIG
SLNO
IRMD

Company Profile

Healthcare Biotechnology
  • Volume Average 791.03K
  • Market Capitalization 700.41M
  • Employee 37
  • CEO Mr. Matthew Pauls J.D., M.B.A.
  • Headquarters Austin,TX,US
  • IPO Date 2017-04-28
  • Website https://www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.